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the process of implantation, trophoblast invasion and placentation demand continuous adaptation and 
modifications between the trophoblast (embryonic) and the decidua (maternal). Within the decidua, 
the maternal immune system undergoes continued changes, as the pregnancy progress, in terms of 
the cell population, phenotype and production of immune factors, cytokines and chemokines. Human 
chorionic gonadotropin (hCG) is one of the earliest hormones produced by the blastocyst and has 
potent immune modulatory effects, especially in relation to T cells. We hypothesized that trophoblast-
derived hcG modulates the immune population present at the maternal fetal interface by modifying the 
cytokine profile produced by the stromal/decidual cells. Using in vitro models from decidual samples we 
demonstrate that hcG inhibits CXCL10 expression by inducing H3K27me3 histone methylation, which 
binds to Region 4 of the CXCL10 promoter, thereby suppressing its expression. hCG-induced histone 
methylation is mediated through EZH2, a functional member of the PRC2 complex. Regulation of 
CXCL10 expression has a major impact on the capacity of endometrial stromal cells to recruit CD8 cells. 
We demonstrate the existence of a cross talk between the placenta (hCG) and the decidua (CXCL10) in 
the control of immune cell recruitment. Alterations in this immune regulatory function, such as during 
infection, will have detrimental effects on the success of the pregnancy.
The coordinated balance between the invading trophoblast and a receptive maternal decidua is critical for the 
success of pregnancy1,2. The process of implantation, trophoblast invasion and placentation demand continuous 
adaptation and modifications between the trophoblast (embryonic) and the decidua (maternal)3–5. Within the 
decidua, the maternal immune system undergoes continued modifications, as the pregnancy progresses, in terms 
of the cell population, phenotype and production of immune factors, cytokines and chemokines6. These adapta-
tion processes are essential for the normal progression of the pregnancy.
The decidua, the pregnant uterine endometrium, has long been considered as a supportive environment for 
the immune cells and the trophoblast present at the implantation site. However, growing evidence suggest that 
decidual stromal cells (DSCs) may play a more active role in the regulation of differentiation, migration and func-
tion of uterine immune cells7 as well as in the protection against infections8.
Immune cells are a major cellular component of the human and rodents’ pregnant uterus, and their specific 
role has been an area of active research. During the first trimester of the human pregnancy, 70% of the leukocytes 
found in the decidua are Natural Killer (NK) cells, 20% to 25% are macrophages, and approximately 1.7% are den-
dritic cells (DCs)9–11. In addition, the uterine T cell population expands across gestation, and are mostly regulatory 
in nature12. The recruitment of immune cells into the uterus is cell specific and their function is locally controlled7. 
Examples include the increase of NK cells at the end of the menstrual cycle, or recruitment of macrophages and 
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DCs during the preimplantation period13. Human endometrial stromal cells (HESCs) are known to produce 
and secrete various chemokines, including Interleukin-8 (IL-8)14,15, growth-regulated oncogene (GRO) α16–18, 
monocyte chemoattractant protein-1 (MCP-1)15,19, macrophage inflammatory protein-1 (MIP-1α)20, regulated 
upon activation normal T cell expressed and secreted (RANTES)21,22 and interferon-induced protein 10 (IP-
10)23. The expression of these cytokines has been suggested to be important in menstruation, infections (bacterial 
and viral), implantation and in the support of early pregnancy24,25. Interestingly, the maintenance of pregnancy 
requires the inhibition of many of these cytokines/chemokines in order to restrict the recruitment of immune 
cells, such cytotoxic CD8 T cells that could endanger the acceptance of the fetus. Furthermore, several reports 
suggest that during pregnancy, the decidua is responsible for actively restricting access of cytotoxic CD8 T cells 
to the maternal-fetal interface26 suggesting that the process of differentiation from endometrial stromal cells into 
decidual cells involves the existence of active mechanisms regulating chemokine expression and function.
Human and animal studies have demonstrated that the cytokine milieu in the uterus is not only different 
between the pregnant and non-pregnant uterus, but it differs between early and late pregnancy6,27,28. Indeed, 
implantation and early trophoblast invasion have been shown to depend on the presence of inflammatory signals 
necessary for the attachment of the embryo to the surface epithelium of the uterus29. However, once implanta-
tion is achieved, the inflammatory environment needs to be reversed into an anti-inflammatory state in order to 
prevent maternal rejection of the embryo30,31. The signals regulating this shift at the implantation site have not 
yet been defined.
Human chorionic gonadotropin (hCG) is one of the earliest hormones produced by the blastocyst and has 
potent immune modulatory effects, especially in relation to T cells32–34, B cells and dendritic cells35,36. hCG has 
been suggested to induce the immune modulatory changes in the phenotype and function of immune cells by 
either a direct pathway that involves the direct binding of hCG to its receptor on T and B cells34,37, or indirect 
pathways by inducing changes in regulatory cell populations such as dendritic cells38–40 or decidual/stromal cells. 
The interaction between hCG and stromal cell differentiation and immune regulatory function is unknown.
Several of the modifications taking place in the uterus in preparation for and during pregnancy are epigenetic 
modifications in response to local and systemic signals. The Polycomb-group (PcG) proteins make up the two 
Polycomb repressor complexes, PRC1 and PRC241 and are major regulators of cell differentiation. Each complex is 
composed of known core proteins, which represent the evolutionary conserved components of the complex42–45. 
Fine-tuning of the different components of each PRC has been observed in different cell types and in different cel-
lular states46. In humans, PRC1 is composed of core proteins Bmi-1/Mel-18, CBX, RING1, and PHC while PRC2 
is composed of EZH2, EED, and SUZ12. Multiple isoforms exist for each PcG protein and therefore, depending 
on the cell type and cellular state, the components of each PRC vary. PRCs suppress gene transcription through 
binding to the chromatin at the polycomb responsive elements (PRE) and promoting methylation47–49. EZH2 
provides the methyltransferase activity on histone lysine residues that is essential for inducing transcriptional 
repression and stable gene silencing. Although it has been shown that the PcG proteins play an important role in 
the differentiation and function of decidual cells, the factors controlling these epigenetic modifications have not 
been elucidated. Previously, Nancy et al.50 reported in mice that CXCL9 and CXCL10, two important chemokines, 
are transcriptionally silenced during decidualization in the mouse uterus. This happened in association with pro-
moter addition of tri-methyl histone H3 lysine 27 (H3K27me3), a repressive histone mark generated by polycomb 
repressive complex 2 (PRC2). H3K27me3 is an epigenetic modification to the DNA packaging protein Histone 
H3 and constitutes a mark that indicates the tri-methylation to the 27th lysine residue of the histone H3 protein. 
This tri-methylation is associated with the downregulation of nearby genes via the formation of heterochromatic 
regions51.
The objective of this study was to characterize the mechanisms associated with the regulation of the chemok-
ine CXCL10 expression during the process of stromal-decidual differentiation. We tested the hypothesis that the 
trophoblast signal hCG, is responsible for the suppression of pro-inflammatory cytokines, specifically CXCL10 
expression by uterine stromal cells by regulating H3K27me3 histone modifications. We report the identifica-
tion of a specific site at the promoter region of CXCL10 modified by H3K27me3 and show that hCG-induced 
H3K27me3 modification requires the recruitment of the PRC2 member EZH2. Furthermore, we describe the 
clinical correlation between circulating hCG and CXCL10 levels during early gestation in normal pregnancies.
Results
Decidual stromal cells (DSCs) secrete a specific cytokine profile that results in decreased CD8 T 
cell migration compared to stromal cells. Our first objective was to determine the capacity of human 
endometrial stromal cells versus decidual cells to recruit immune cells and to characterize their chemokine 
profile. To achieve this objective, we used an in vitro model consisting of a telomerase immortalized human 
endometrial stromal cell line (HESCs) which can undergo in vitro differentiation into decidual cells (DSCs) by 
continued treatment with estrogen, progesterone and cAMP as previously reported and described in the Material 
and Methods52. In short, HESCs were exposed to estrogen, progesterone and cAMP for 5–9 days and the differ-
entiation of HESCs into DSCs was confirmed by morphologic changes such as enlarged, rounded morphology 
compared to the elongated spindle-shaped fibroblastic stromal cells (Fig. 1A) and the increased expression of 
Prolactin and IGFBP-1 (Fig. 1B)52. Afterwards, we evaluated the capacity of these cells to recruit immune cells by 
using a 5 µM trans-well two-chamber migration assay where conditioned media (CM) collected from HESCs or 
DSCs (see M&M for preparation of CM) were added to the bottom chamber as chemoattractant and peripheral 
blood mononuclear cells (PBMCs) (350,000 cells/well) were added to the upper chamber. After 24 h, all the cells 
that migrated into the lower chamber were collected and the number of T cells (CD4 and CD8) was evaluated 
by flow cytometry. We observed a significantly higher number of T cells present in the chambers containing 
HESCs’ CM (18,543 ± 115 T cells) compared to the chambers containing CM from DSCs (10,007 ± 1654 T cells) 
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(p < 0.05) (Fig. 2B). The proportion of recruited CD4 and CD8 T cells were significantly reduced in the chambers 
containing CM from DSCs compared to the chambers containing HESCs’ CM (Fig. 2A,C)
These findings suggest that HESCs are highly effective in recruiting T cells; however, differentiation into DSCs 
is associated with a significant drop in their recruitment capacity.
Cytokines and chemokines are the main mediators of immune cell recruitment; consequently, we evaluated, 
using Luminex analysis, whether there were differences in the cytokine and chemokine profile between HESC and 
DSCs that could explain the observed differential capacity to recruit T cells between these two cell types. Table 1 
summarizes the cytokine/chemokine profile from supernatants obtained from these two cell types. HESCs are 
characterized by the secretion of pro-inflammatory cytokines, IL6, IL-12, IL-17, IFN-γ and chemokines IL-8, 
G-CSF CXCL-10, MIP-1α, VEGF and CCL5 (RANTES) (Table 1); however, upon differentiation into DSC cells, 
we observed a significant reduction in the secretion levels of these pro-inflammatory cytokines and chemokines 
(Table 1).
CXCL10 is a potent chemoattractant for CD8 + T cells and is highly expressed in the supernatant of HESCs 
but its expression is dampened upon differentiation into DSC; hence, we hypothesized that the decrease in migra-
tion of CD8 + T cells with the DSCs CM might be due to the inhibition of CXCL10 expression after deciduali-
zation. Accordingly, we sought to elucidate the potential mechanisms responsible for the regulation of CXCL10 
expression in HESCs/DSCs and its impact on T cell recruitment.
hCG/cyclic AMP pathway regulates CXCL10 expression during cellular differentiation. In order 
to determine whether the process of differentiation from stromal cells into decidua cells is associated with the 
changes on CXCL10 expression, we evaluated CXCL10 mRNA levels in HESCs before and after differentiation 
into DSCs. Similar to the findings with the secreted protein, the process of decidualization is associated with tran-
scriptional inhibition of CXCL10, demonstrated by decreased levels of CXCL10 mRNA in DSCs, which correlated 
with lower levels of secreted protein expression compared to the HESCs (Fig. 3A,B). Since estrogen and proges-
terone are known to be the main hormones involved in the process of decidual differentiation; we first tested the 
effect of either estrogen or progesterone on CXCL10 expression by stromal cells. Interestingly, neither estrogen 
nor progesterone were responsible for the modulatory effect on CXCL10 expression levels during decidualization 
(Fig. 3C). However, we did observe a significant inhibitory effect on CXCL10 mRNA and protein expression fol-
lowing cAMP treatment, the other major mediator of decidualization53 (Fig. 3A–C); suggesting that factors that 
could activate cAMP might have modulatory effects on CXCL10 expression.
hCG is one of the early factors secreted by the trophoblast and is known to have immune modulatory effects 
during pregnancy, especially with regards to the recruitment of regulatory T and B cells33,34. The cellular effects 
of hCG are mediated through the LH receptor (LHR), a G-protein coupled receptor, and ligation of the receptor 
results in an increase in intracellular cAMP, its secondary messenger whose resulting protein cascades affect tar-
get gene expression54. Therefore, we hypothesize that hCG, though the induction of cAMP could inhibit recruit-
ment of CD8+ T cells by suppressing CXCL10 expression in endometrial stromal cells. To test this hypothesis, 
Figure 1. In vitro model of decidualization. A human endometrial stromal cell line (HESCs)52 was decidualized 
with 10 nM estradiol, 1 uM medroxyprogesterone acetate, and 500 uM 8-bromo cyclic AMP (cAMP) for 
7 days. (A) Morphological changes associated with the decidualization process. The left panel shows the 
untreated HESCs, while the right panel shows the decidualized cells (DCS) after treatment with estradiol, 
medroxyprogesterone acetate, and 8-bromo cyclic AMP. (B) Increased expression of Prolactin and IGFBP1 in 
decidualized cells (DSC) compared to HESC. Data presented as mean ± SD and are shown for 6 independent 
experiments with each done in triplicate. *p < 0.001.
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we first evaluated the overall effect of hCG on cytokine/chemokine expression by HESCs. As shown in Table 1, 
column 3, hCG treatment had a notable inhibitory effect on HESCs’ cytokine and chemokine expression profile, 
similar to the one observed with the process of differentiation into decidual cells (Table 1).
Next, we characterized the potential transcriptional regulatory role of hCG on HESC’s CXCL10 expression 
by treating HESCs with hCG and determining CXCL10 mRNA expression. As shown in Fig. 4, HESCs treated 
with hCG revealed decreased CXCL10 mRNA expression (Fig. 4A) and this effect was dose and time dependent, 
further supporting the specificity of its effect (Fig. 4B,C). The inhibitory effect observed with hCG resembles the 
one determined with cAMP (Fig. 3).
hCG/cyclic AMP pathway is an epigenetic regulator of CXCL10 expression by inducing histone 
methylation. Epigenetic modifications, such as histone methylation, play a central role in the regulation of 
cytokines and chemokines expression55; therefore, we hypothesized that the hCG/cAMP pathway may silence 
Figure 2. Recruitment of immune cells by stromal cell- derived factors. Supernatants from HESC and 
decidualized HESC (DSC) cells were collected after 5 days of culture (equal confluence) and used as conditioned 
media (CM) for testing their effect on the migration of peripheral blood mononuclear cells (PBMC) using a 
two- chamber migration assay. PBMCs were added to the upper chamber for 24 h. The migrated cells (lower 
chamber) were collected, phenotyped, and counted by flow cytometry. (A) Representative figure of the different 
cell types collected in the lower chamber recruited by HESC and DSC’s conditioned media. Both CD4 and CD8 
T cells migrated towards HESC CM and DSC CM. (B) Quantification of the total number of T cells recruited 
towards conditioned media obtained from HESC and DSC. Data shown are for 6 independent experiments with 
each group done in triplicate. *p < 0.001. (C) Flow Cytometry Analysis of CD4 and CD8 T cells. Percentage 
of CD4 and CD8 T cells recruited by DSC CM compared to HESC CM. DSC CM recruits significantly 
lower number of CD4 and CD8 T cells compared to HESC CM. Data presented as mean/SEM and are for 6 
independent experiments with each group done in triplicate. *p < 0.05. **p < 0.01.
Cytokine HESC DSC* HESC + hCG*
CXCL10 307.13 +/− 34.45 30.18 +/− 3.76 (<0.05) 16.51 +/− 9.38 (<0.05)
GRO-alpha 484.59 +/− 90.62 0 (<0.05) 0 (<0.05)
IL-12 33.64 +/− 4.68 6.25 +/− 0.58(<0.05) 15.89 +/− 3.15 (<0.05)
IL-17 10.27 +/− 1.26 3.90 +/− 1.74(<0.05) 2.26 +/− 0.1 (<0.05)
G-CSF 18.72 +/− 3.02 4.63 +/− 0.91 (<0.05) 0.83 +/− 1.05 (<0.05)
IFN-γ 22.49 +/− 1.5 0 (<0.05) 0 (<0.05)
IL-8 18650.72 +/− 13471.22 438.30 +/− 141.79 (<0.05) 447.75 +/− 90.90 (<0.05)
MCP-1 2229.11 +/− 517.63 1157.14 +/− 183.77 (NS) 29.2 +/− 1.73 (<0.05)
MIP-1 alpha 0.44 +/− 0.06 0 (NS) 0 (NS)
RANTES 429.68 +/− 30.10 48.44 +/− 4.57 (<0.05) 10.52 +/− 4.10 (<0.05)
VEGF 127.15 +/− 20.92 22.85 +/− 1.4 (<0.05) 175.14 +/− 29.13 (NS)
Table 1. Cytokines/Chemokines expression levels. *Differential expression in relation to HESC.
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the promoter of CXCL10 (the human gene that codes for CXCL10) by histone methylation. As indicated above, 
H3K27me3 modification is associated with gene shutting down target gene transcription56,57. First, we deter-
mined whether the hCG/cAMP pathway could affect global H3K27 methylation by treating HESCs with hCG 
or cAMP for 2 h and evaluating H3K27me3 modification by western blot analysis. As shown in Fig. 5A, HESCs 
cells treated with either hCG or cyclic AMP showed increased levels of H3K27me3 modification when compared 
to non-treated cells (Fig. 5A,B). Furthermore, when we expose HESCs to increasing concentrations of hCG, we 
observed a dose dependent increase on H3K27me3 modification (Fig. 5C,D). Total H3 was not affected by any 
of these treatments, confirming that the effect is associated with increasing methylation of H3K27 (Fig. 5A–D).
Next, we sought to determine the molecular mechanism of how hCG mediates H3K27me3 modification. The 
PRC2 complex is the main regulator of H3K27me3 modification through the specific histone methyltransferase, 
EZH2. EZH2 catalyzes the methylation of Histone 3 at Lysine 27 (K27)45. Hence, we evaluated EZH2 in the reg-
ulation of H3K27me3 in HESC by using an inhibitor for EZH2, GSK126. Thus, DSCs, which express high levels 
of H3K27me3 and low levels of CXCL10, were treated with GSK126 (2μM) for 24 h followed by evaluation of 
CXCL10 mRNA expression and H3K27me3 by western blot analysis. Treatment of DSCs with GSK126 decreased 
H3K27me3 modification, as determined by western blot analysis (Fig. 6A); and, interestingly, correlated to 
enhanced CXCL10 mRNA expression (5-fold) (Fig. 6B). We then determined whether hCG effect on H3K27me3 
could be mediated through the regulation of EZH2 expression. Thus, HESCs were treated with hCG and EZH2 
mRNA expression was determined by qPCR. We observed that hCG treatment had a modest, but significant 
effect on EZH2 mRNA expression (1.5-fold increase) (Fig. 6C). These findings further suggest an epigenetic reg-
ulation of CXCL10 expression in endometrial stromal cells.
Specific Binding of H3K27me3 to the CXCL10 promoter in human decidual tissues. So far, we 
demonstrated in vitro, using cell lines, that hCG treatment affected H3K27me3 modification levels and correlates 
with CXCL10 mRNA and protein expression. Our next objective was to determine whether these findings are also 
present in freshly collected decidual tissue that has not undergone any in vitro manipulation. The main justifica-
tion to use the whole decidual tissue is to avoid the potential non-specific effect of cell isolation and cell culture. 
Thus, decidual samples were obtained from term, non-labored, uncomplicated pregnancies undergoing sched-
uled cesarean delivery. Using these freshly collected decidual samples we then evaluated whether H3K27me3 
Figure 3. Regulation of CXCL10 expression in stromal versus decidual cells. (A) Effect of cAMP and 
decidualization on CXCL10 mRNA expression. HESC were treated with 500 uM 8-bromo cAMP alone or 
decidualized with 10 nM estradiol, 1 uM medroxyprogesterone acetate, and 500 uM 8-bromo cyclic AMP for 7 
days. Note the significant inhibition of CXCL10 mRNA expression by cAMP in HESC, similar to the decrease 
observed in the decidualized cells (DSC) *p < 0.05. Data presented as mean ± SD and are from 3 independent 
experiments with each group done in triplicate. (B) Quantification of CXCL10 protein expression in HESC 
treated with cAMP or decidualized with estrogen, progesterone and cAMP. cAMP treatment and decidualized 
cells (DSC) are associated with decreased CXCL10 protein expression. *p < 0.001. **p < 0.05. Data presented 
as mean ± SD and are from 3 independent experiments with each group done in triplicate. (C) Effect of 
estrogen, progesterone and cAMP on CXCL10 mRNA expression. HESC were treated with 10 nM estradiol, 1 
uM medroxyprogesterone acetate (MPA), and 500 uM 8-bromo cAMP individually or under the combination 
of estradiol, MPA and cAMP for 7 days. CXCL10 mRNA was determined by qPCR. Note that only cAMP 
has a major effect on CXCL10 mRNA expression. Data presented as mean ± SD and are from 3 independent 
experiments with each group done in triplicate.
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modification is present in the tissues and if is responsible for the suppression of CXCL10 gene expression. First, 
we determined the enrichment of this histone mark on the CXCL10 promoter by performing chromatin immuno-
precipitation using an anti-H3K27me3 antibody on freshly collected decidual tissue. After immune precipitation 
Figure 4. Regulation of CXCL10 expression by hCG in human endometrial stromal cells (HESC). (A) HESC 
were treated with hCG 100 IU/ml for 24 h and CXCL10 mRNA expression was determined by qPCR. Note 
the significant decrease of CXCL10 mRNA expression after hCG treatment. Data presented as mean ± SD 
and are for 6 independent experiments with each group done in triplicate *p < 0.005. (B) Time response to 
hCG treatment (100 IU/ml). HESC were treated with hCG (100 IU/ml) for 2, 12 and 24 h and CXCL10 mRNA 
expression was determined by qPCR. CXCL10 mRNA expression decreased within 2 hours of hCG treatment 
and remained low up to 24 hours of treatment. (C) Dose response to hCG treatment. HESC were treated with 
increasing concentrations of hCG and CXCL10 mRNA expression was determined by qPCR. CXCL10 mRNA 
expression in HESC decreased in a dose dependent manner.
Figure 5. Regulation of H3K27me3 expression by hCG and cAMP in human endometrial stromal cells. (A) 
hCG and cAMP induce H3K27me3 in HESC. HESC were treated with hCG (100 IU/mL) or cAMP (500 uM) 
and H3K27me3 expression was determined by Western blot analysis. Representative western blot analysis 
showing hCG and cAMP enhanced H3K27me3 expression in HESCs. (B) Quantification of the western blot 
analysis showed in figure A. Data is presented as Relative Intense Units (RIU) as an average of 3 independent 
experiments. *p < 0.001. (C) Dose response effect of hCG on H3K27me3 expression. HESC were treated with 
increasing concentrations of hCG for 24 h followed by the determination of H3K27me3 expression by Western 
blot. hCG induces a dose dependent increase on H3K27me3 expression. Data is representative of 3 independent 
experiments done in triplicate. (D) Quantification of the western blot analysis showed in figure C. Data is 
presented as Relative Intense Units (RIU) as an average of 3 independent experiments.
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with the anti-H3K27me3 antibody we evaluated the enrichment of the histone mark in the CXCL10 promoter 
by using eight pairs of primers designed to span the 1000 bp upstream of the human CXCL10 gene. In human 
term uncomplicated non-labor decidua, we observed enrichment of H3K27me3 in Region 4 (505–601 base pairs 
upstream) of the human CXCL10 promoter (Fig. 7A,B). There was no appreciable enrichment in regions 1–3, 
or 5–8 (Fig. 7A,B). These findings were validated and quantified in six human decidua specimens (Fig. 7C,D). 
Only in region 4 we are able to obtain quantitative enrichment of H3K27me3 in the CXCL10 promoter (Fig. 7D). 
Figure 7C shows a representative DNA gel of the PCR product after chromatin immunoprecipitation demonstrat-
ing enrichment of the H3K27me3 to Region 4 of the CXCL10 promoter in human decidua samples. The presence 
of the H3K27me3 mark at region 4 of the CXCL10 promoter correlates with low levels of CXCL10 mRNA expres-
sion in decidual tissue compared to stromal cells (Fig. 7E). Stroma cells are used as positive control for CXCL10 
expression.
hCG regulates the Binding of H3K27me3 to the CXCL10 promoter in human stromal 
cells. Having identified Region 4 as the site for H3K27me3 modification at the CXCL10 promoter in decidual 
tissues, our next objective was to determine whether hCG could promote this modification. Accordingly, we 
treated HESCs, expressing high levels of CXCL10, with hCG (100 IU/ml) for 2 h, followed by chromatin immuno-
precipitation and PCR for enrichment of H3K27me3 mark at the CXCL10 promoter. Our data showed a 15-fold 
increased enrichment of H3K27me3 modification at Region 4 of the CXCL10 promoter in HESCs treated with 
hCG compared to non-treated cells (Fig. 8A). Similar as reported with decidual tissues (Fig. 7), no modifications 
were found in the other regions; confirming the specificity for region 4 of the CXCL10 promoter.
We then compared whether similar effect is observed during the in vitro process of differentiation into decid-
ual cells. Thus, HESC were exposed to estrogen, cAMP and progesterone for 5 days in order to induce decidu-
alization, followed by chromatin immunoprecipitation and PCR for enrichment of the H3K27me3 mark at the 
CXCL10 promoter. As shown in Fig. 8B, we confirmed that the process of differentiation from HESCs to DSCs 
is associated with the enrichment of the histone mark to region 4 of the CXCL10 promoter (42-fold increase; 
p < 0.01) (Fig. 8B). No changes were observed in the other regions (Fig. 7B,D).
Bacterial Lipopolysaccharide (LPS) inhibits H3K27me3 modification and induces CXCL10 
expression in term human decidual tissue through the histone demethylase JMJD3. Our 
next objective was to determine the potential signals that could disrupt the regulation of CXCL10 expression 
by decidual cells. Since bacterial infections are a major cause of pregnancy complications and are able to induce 
and inflammatory process at the maternal/fetal interface including the expression of inflammatory cytokines/
chemokines such as CXCL1058, we hypothesized that bacterial signals could induce CXCL10 expression by 
modifying the H3K27me3 mark and consequently promote the recruitment of maternal CD8+ T cells. To test 
this hypothesis, first we used the organ culture model of normal human term decidual tissue obtained from 
non-labored cesarean deliveries which, as described above, express low levels of CXCL10 and express high lev-
els of the H3K27me3 mark at Region 4 of the CXCL10 promoter. Thus, decidual tissues were exposed to PBS 
(Control) or lipopolysaccharide (LPS, 100 ng/mL) for 24 h and evaluated for the presence of H3K27me3 mark 
at region 4 of the CXCL10 promoter by chromatin immunoprecipitation using the anti-H3K27me3 antibody. In 
addition, we determined the expression of CXCL10 mRNA and protein by qPCR and Luminex assay, respectively. 
Decidual tissue samples exposed to control PBS showed strong enrichment of the H3K27me3 mark at Region 4 
of the CXCL10 promoter (Fig. 9A), which correlates with low levels of CXCL10 mRNA and protein expression 
Figure 6. Regulation of EZH2 expression by hCG in human endometrial stromal cells. (A) Treatment of 
HESC with the EZH2 inhibitor GSK126 (2μM) decreases H3K27me3 expression. HESC were treated with 
GSK126 (2μM) for 24 h followed by the evaluation of H3K27me3 expression by Western blot analysis. Note 
the decrease of H3K27me3 expression in the presence of GSK126. Representative Western blot analysis from 6 
independent experiments. (B) Treatment of HESC with the EZH2 inhibitor GSK126 (2μM) increases CXCL10 
mRNA expression. HESC were treated with GSK126 (2μM) for 24 h followed by the evaluation of CXCL10 
mRNA expression by qPCR. Treatment with GSK126 is associated with significant increase in CXCL10 mRNA 
expression. *p < 0.002. Data shown as mean + SD and are for 6 independent experiments. (C) Effect of hCG on 
EZH2 mRNA expression. HESC were treated with hCG (100 IU/mL) for 24 h and CXCL10 mRNA expression 
was determined by qPCR. hCG treatment enhances EZH2 mRNA expression in HESC. *p < 0.05. Data shown 
as mean + SD and are for 3 independent experiments.
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Figure 7. Identification of a novel site of epigenetic regulation in the CXCL10 promoter in term human 
decidual tissue. (A) Diagram of the CXCL10 promoter region. Eight specific primers were designed to cover 
the full length of the CXCL10 promoter region (IP-10 = CXCL10). (B) Chromatin immunoprecipitation 
was performed on human decidual samples collected from normal term non-labored placentas delivered 
by cesarean delivery. Decidual samples were crosslinked, sonicated and immunoprecipitated using an anti-
H3K27me3 antibody. The DNA enriched with the H3K27me3 was purified and amplified by qPCR for the 
different regions of the CXCL10 promoter. Immunoprecipitation of H3K27me3 and PCR amplification of the 
DNA sequence bound by the histone demonstrated a strong band at Region 4 (505–601 base pairs upstream 
of the CXCL10 gene) in the promoter region of CXCL10 gene. No bands were detected at regions 1–3 or 5–8, 
indicating that the histone mark was not enriched in those regions. (C) PCR amplification of the DNA from 
Region 4 of the CXCL10 promoter that was bound by the H3K27me3 after immunoprecipitation using an 
anti-H3K27me3 antibody. Representative figure of 6 independent decidual samples. (D) Quantification of the 
enrichment of the DNA sequence in the different regions of the CXCL10 promoter. Note that only Region 4 
reveled binding to the H3K27me3 after ChIP qPCR. n = 6 human decidual tissue samples. (E) Relative CXCL10 
mRNA expression levels from decidual tissue samples in relation to stromal cells. *p < 0.05. n = 6 human tissue 
samples.
Figure 8. hCG regulates CXCL10 expression and secretion by increasing H3K27me3 histone enrichment in 
Region 4 of the CXCL10 promoter. (A) HESC were treated with either vehicle or hCG (100 IU/ml). The cells 
were crosslinked, sonicated and immunoprecipitated using an anti-H3K27me3 antibody. The DNA enriched 
with the H3K27me3 was purified and amplified for Region 4 of the CXCL10 promoter. The results were 
quantified by ChIP qPCR. Note the significant enrichment of Region 4 bound to H3K27me3 in cells treated 
with hCG. *p < 0.05. Data shown are for 3 independent experiments. (B) Enrichment of the H3K27me3 mark 
in the CXCL10 promoter from HESC undergoing decidualization. HESC were decidualized with estrogen, 
progesterone and cAMP for 5 days. Chromatin immunoprecipitation was performed in HESC and decidualized 
stromal cells using an anti-H3K27me3 antibody. The enrichment was quantified using ChIP qPCR. Note the 
significant enrichment of Region 4 bound to H3K27me3 in decidualized cells compared to HESC. **p < 0.002. 
Data shown for 3 independent experiments.
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(Fig. 9C,D). That was not the case for the decidual samples treated with LPS where we observed a decrease of the 
H3K27me3 mark at Region 4 of the CXCL10 promoter (Fig. 9A). Using ChIP qPCR we quantified the level of 
enrichment for H3K27me3 in Region 4 of CXCL10 promoter and confirmed the decrease of the H3K27me3 mark 
following LPS treatment compared to the control vehicle (Fig. 9B). Changes in the presence of H3K27me3 mod-
ification at the CXCL10 promoter correlated with the expression levels of CXCL10. Indeed, our data showed that 
LPS treatment, by decreasing the presence of H3K27me3 modification prompted increase on CXCL10 expression 
at the mRNA (Fig. 9C) and protein level (Fig. 9D). We observed a 10-fold increase in CXCL10 mRNA expression 
in the LPS treated group compared to the control vehicle (Fig. 9C). Similarly, at the protein level we observed a 
significant increase in the concentration of secreted CXCL10 in the LPS treated group (32,832.56 ± 1, 902.12 pg/
mL) compared to control no treatment (13,886,86 ± 1,254.27 pg/mL*p < 0.05) (Fig. 9D). These findings further 
demonstrate that the H3K27me3 modification is present in human decidual tissue, regulating CXCL10 expression 
and can be modified by signals induced by bacterial products such as LPS.
Next, we evaluated the mechanism how LPS decreases the H3K27me3 mark at Region 4 of the CXCL10 pro-
moter. We screened for changes in the expression of known H3K27me3 histone demethylases such as KDM6A 
and JMJD359 in response to LPS treatment and found that the mRNA expression of JMJD3, a histone demeth-
ylase specific to the methylated histone H3K27me3, was affected by LPS treatment. Thus, when decidual organ 
cultures were exposed to PBS (Control) or LPS (100 ng/mL) for 24 h and evaluated JMJD3 mRNA expression, 
decidual organ cultures exposed to LPS showed a 3-fold increase in JMJD3 mRNA expression compared to the 
PBS control (p < 0.05) (Fig. 10A). The increase in JMJD3 expression correlated with LPS-induced decrease of 
H3K27me3 modification from the CXCL10 promoter (Fig. 9A,B) and increased CXCL10 mRNA expression and 
protein secretion (Fig. 9C,D).
To further confirm the role of JMJD3, we treated the decidual organ cultures with GSK-J4, a specific JMJD3 
inhibitor, in the presence or absence of LPS and then examined CXCL10 expression levels. As shown in Fig. 10B, 
pre-treatment of decidual organ cultures with the GSK-J4 reversed the effect of LPS on CXCL10 mRNA expres-
sion. While LPS treatment induced a 19-fold increased on CXCL10 mRNA expression, the presence of GSK-J4 
significantly reduced LPS-induced CXCL10 mRNA expression (Fig. 10B; p < 0.05). GSK-J4 treatment alone did 
not affect CXCL10 mRNA expression (Fig. 10B). This data demonstrates that infection can induce a strong and 
quick inflammatory response by decreasing the H3K27me3 modification through the induction of the expression 
of the histone demethylase JMJD3.
Figure 9. Effect of LPS on CXCL10 expression and secretion. (A) Human term decidua tissues were treated 
with LPS (100 ng/ml) for 24 followed by chromatin immunoprecipitation using an anti-H3K27me3 antibody. 
The DNA enriched with the H3K27me3 was purified and amplified by qPCR for Region 4 of the CXCL10 
promoter. Note the decreased binding of the H3K27me3 to region 4 of the CXCL10 promoter observed in 
cells treated with LPS compared to the control (PBS) treated group. Representative figure of 6 independent 
experiments. (B) Quantification of the enrichment of the DNA sequence of region 4 of the CXCL10 promoter 
bound to H3K27me3. The enrichment was quantified using ChIP qPCR and reveled decreased enrichment 
in decidual samples exposed to LPS. p < 0.05. (C) Effect of LPS on CXCL10 mRNA expression. Human term 
decidua tissue samples were treated with LPS (100 ng/ml) for 24. CXCL10 mRNA expression was determined 
by qPCR. LPS treatment induces a significant increase on CXCL10 mRNA expression in human term decidua 
tissues n = 6, *p < 0.05. (D) Human term decidua tissues were treated with LPS (100 ng/ml) for 24 followed 
by evaluation of CXCL10 protein expression by Luminex. LPS induces CXCL10 protein secretion in decidual 
samples. n = 6, *p < 0.001.
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LPS removal of H3K27me3 modification in DSCs results in increased recruitment of CD8 + t 
cells. Finally, we determined whether LPS, by decreasing the H3K27me3 modification and enhancing CXCL10 
expression could affect the capacity of DSCs to recruit T cells. Thus, we used the same trans-well migration assay 
as described in Fig. 2. PBMC were added to the upper chamber and then exposed to CM in the lower chamber 
obtained from: (1) DSCs treated with vehicle (control) or (2) DSCs treated with LPS (100 ng/mL) for 48 h. This 
concentration of LPS has no detrimental effect on DSCs60–63. As shown in Fig. 10C, LPS treatment of HESC and 
DSCs enhances the recruitment of T cells. Indeed, CM from DSCs treated with LPS attracted more T cells than 
CM from non-treated DSCs (11,832 ± 821.7 vs 1905 ± 165, p < 0.05). A high percentage of the recruited cells 
were CD8 + and CD4 + T cells (Fig. 10D).
Inverse correlation between hCG and CXCL10 levels in early pregnancy. So far as we have 
described in vitro, there is an inverse correlation between hCG and CXCL10 expression. Since CXCL10 expression 
levels has been shown to be higher during human embryo implantation64 and subsequently decreased throughout 
the pregnancy65, we explored whether we could detect and determine in the serum of pregnant women a potential 
correlation between circulating hCG and CXCL-10 in the first 8 weeks of pregnancy, a period when hCG pro-
duction increases as result of successful placentation. Although circulating cytokines can be affected by multiple 
processes taking place in the body, it is the only non-invasive source for evaluating some of the changes occurring 
during pregnancy66. To achieve this objective, we recruited an IVF cohort where we were able to monitor the day 
of implantation and collect samples from the earliest stages of pregnancy (between 3 and 6 weeks of gestation) 
and measured hCG and CXCL10 in the serum of these pregnant women throughout the first trimester of preg-
nancy. We detected CXCL10 in the serum of pregnant women as early as 9 days after embryo transfer and it serum 
levels remained constant during the subsequent days (SFig. 3). Circulating hCG levels gradually increased as 
pregnancy progresses (Fig. 11A); interestingly, when we look at the ratio between CXCL10 and hCG we observed 
an inverse correlation as the pregnancy progressed (Fig. 11B). This is a noteworthy association since CXCL10 is 
known to be high during implantation and then silenced to prevent the recruitment of T cells64.
Figure 10. Role of JMJD3 in the regulation of CXCL10 expression and secretion. (A) Expression of JMJD3 in 
human decidual tissue. Human term decidual tissues were treated with LPS (100 ng/ml) and JMJD3 expression 
was determined by qPCR. LPS treatment enhances JMJD3 mRNA expression. n = 6, *p < 0.05. (B) Inhibition 
of JMJD3 function with the inhibitor GSKJ4 prevents LPS-induced CXCL10 expression. Human term decidual 
tissues were treated with LPS (100 ng/ml) in the presence or absence of GSKJ4, an inhibitor of JMJD3 for 24 h. 
CXCL10 mRNA expression was determined by qPCR. The presence of GSKJ4 inhibits LPS induced CXCL10 
expression. *p < 0.05. (C) Quantification of the total number of T cells recruited towards conditioned media 
obtained from HESC and DSC in the presence or absence of LPS treatment (100 ng/ml). Transwell migration 
assays were performed using peripheral blood mononuclear cells and conditioned media from HESC and DSC 
treated with LPS or vehicle (control). LPS treatment is associated with increased number of T cells collected in 
the lower chamber (recruitment chamber). n = 6 independent experiments. Each group was done in triplicates. 
*p < 0.001. (D) Flow Cytometry Analysis of CD4+ and CD8+ T cells. Percentage of CD4+ and CD8+ T cells 
recruited by DSC CM in relation to HESC CM was determined by flow cytometry. CD4+ and CD8+ T cells 
were identified in the Transwell migration assays. Representative flow cytometry from four independent 
experiments.
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Discussion
In this study, we describe the epigenetic role of hCG in the regulation of CXCL10 in the human decidua. We 
report for the first time, the identification of a specific site for the repressive histone mark H3K27me3 in the 
promoter of the human CXCL10gene (Region 4, 505–601 kb upstream). Furthermore, we describe the role of 
hCG as a regulator of CXCL10 expression by controlling the H3K27me3 mark through the expression of the 
histone methyltransferase, EZH2. We show that this mark can then be modified by bacterial products leading 
to an increase in CXCL10 expression and enhancement of the recruitment of pro-inflammatory CD8 + T cells. 
The modification of H3K27me3 mark is mediated by JMJD3, a histone demethylase. Our studies show an active 
epigenetic crosstalk between the trophoblast and decidua that results in chemokine suppression. These findings 
are relevant because they describe a novel mechanism of fetal-maternal anti-inflammatory regulation that can be 
disrupted during infection, potentially leading to inflammation and preterm birth.
One important issue to recognize is that not all inflammation in pregnancy is detrimental. The correct timing 
of inflammation is essential to a healthy pregnancy. For example, it is well established that implantation in the 
first trimester is a pro-inflammatory event67–71 as is labor at the end of the third trimester72–75. On the other hand, 
the second trimester of pregnancy is characterized by an anti-inflammatory profile31,76. In pathological states, 
shifts towards a pro- inflammatory profile before term are associated with preterm birth77–83. Therefore, tight 
regulatory control of inflammation between the fetus/trophoblast unit and the decidua is critical in preventing 
preterm birth.
CXCL10 (IP-10) is a 77 amino acid, 10kDA protein that belongs to the CXC family of chemokines84, and has 
been shown to have pleiotropic biological activities23. CXCL10 is the most potent chemoattractant for cytotoxic 
CD8 + T cells85 and elevated levels of CXCL10 in maternal serum, amniotic fluid, and neonatal cord blood have 
been associated with infection and preterm birth21,86–88. In the mouse, it was described ex vivo that the promoter 
region of the chemokines CXCL9 and CXCLl10 revealed elevated levels of the repressive histone mark H3K27me3 
in DSCs versus myometrial cells, which was then confirmed in vivo26. Methylation of histone 3 at Lysine 27 (K27) 
is one of the most well-described epigenetic modifications. When H3K27 is trimethylated to H3K27me3, it is 
tightly associated with its target gene promoter, inactivating the promoter, and consequently shutting down target 
gene transcription50,56,57. These findings suggest that epigenetic modifications of stromal/decidual cells are critical 
regulators of these chemokines and consequently of the immune regulation at the maternal fetal interface.
CXCL10 is a potent pro-inflammatory chemokine whose regulation appears to be important during preg-
nancy. Human cohort studies have shown that not only does CXCL10 expression increase with normal term 
labor (as do other inflammatory cytokines), but importantly, elevated levels of CXCL10 are associated with pre-
term birth and chorioamnionitis, suggesting that CXCL10 suppression in the decidua is necessary for the normal 
course of pregnancy21,87,89. Recently, the notion of a decidual clock has been proposed, wherein “timing of labor” 
is dependent on the suppression and release of certain elements at the correct timepoint during pregnancy. In the 
beginning of pregnancy, suppressive factors function to maintain the pregnancy and prevent miscarriage. The 
Figure 11. hCG and CXCL10 expression ratio throughout early gestation. Circulating levels of hCG and 
CXCL10 were measured using ELLA assay in serum samples collected from normal pregnant women during the 
first 4 weeks of pregnancy. (A) hCG is detected in the serum as early as 9 days after embryo transfer and shows 
a steady increase in the following days. (B) Ratios of CXCL10 and hCG across gestational age were determined 
in blood samples collected from IVF pregnancies. The line represents the mean estimation by LOWESS and the 
colored areas the 95% confidence intervals of the mean estimation. CXCL10:hCG ratios decreased in normal 
pregnancies in relation to gestational age.
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suppression is then released at the end of pregnancy and allows labor to occur90. Our data support this theory of 
the decidual clock by describing the regulation of CXCL10 in the decidua. By secreting hCG in the beginning of 
the pregnancy, the fetal/placental unit works to “set the timing” on the decidual clock, to suppress inflammatory 
mediators such as CXCL-10. Based on our data, we propose that hCG is the fetal anti- inflammatory factor of 
pregnancy (Fig. 12).
Our data support hCG’s anti-inflammatory and tolerance- promoting functions. Human chorionic gonadotro-
pin, a factor secreted by the trophoblast, has already known immunological properties: It promotes the induction 
and activation of regulatory T cells, and these cells are necessary for the successful establishment of pregnancy33,34. 
hCG treatment of dendritic cells prior to conception induces regulatory T cell expansion and leads to decreased 
spontaneous abortion in mice35. In addition, hCG stimulates macrophage function and activation91,92. In our 
study, hCG and its downstream messenger cyclic AMP- treatments both suppress CXCL10 expression and secre-
tion in stromal cells. CXCL10 suppression supports the anti-inflammatory function of hCG. CXCL10 suppression 
also results in decreased CD8 + T cell migration in decidual cells compared to stromal cells. This data is in line 
with others who have found that hCG down-regulates CD8 + T cells in pregnancy93. Furthermore, hCG sup-
presses not only CXCL-10, but other pro-inflammatory cytokines as well, such as GRO-alpha, IL-8, IL-17, and 
RANTES. Kokdehoff and others also found that hCG decreases inflammatory cytokines in women treated with 
hCG prior to IVF94. However, our data go beyond mere description, and we characterize the mechanism by which 
the fetal factor hCG suppresses CXCL10 expression in decidual cells as it may promote maternal tolerance.
We describe how the fetus/placental unit is an active participant in the process of fetal-maternal tolerance: It 
acts through hCG using epigenetic mechanisms to suppress inflammation. Our data illustrate a novel role of hCG 
as a functional epigenetic regulator suppressing inflammation. Treatment of stromal cells with hCG upregulates 
EZH2, a specific histone methyltransferase, enriching the repressive histone mark H3K27me3 in Region 4 of 
the CXCL10 promoter. This enrichment results in decreased expression and secretion of CXCL-10. In addition, 
enrichment of the H3K27me3 (and subsequent suppression of CXCL-10) also occurred during decidualization 
with cyclic AMP. This data supports a role of hCG in maintaining the normal state of pregnancy.
We also show how infection can induce inflammation and break the fetal-maternal tolerance by disrupting the epi-
genetic mechanism. In our organ culture experiments using term uncomplicated human samples, we are able to induce 
CXCL10 expression and secretion with LPS treatment. Moreover, we show that LPS treatment decreases the enrichment 
of H3K27me3 in Region 4 of the CXCL10 promoter. LPS affects H3K27me3 methylation by inducing JMJD3, a histone 
demethylase, which is also seen in the regulation of other pro-inflammatory cytokines in HUVEC cells95.
In conclusion, our data demonstrates how the fetus/trophoblast unit actively participates in regulating inflam-
mation at the maternal-fetal interface in order to promote pregnancy. The epigenetic inhibition of CXCL10- 
mediated inflammation is promoted by hCG on stromal cells. However, in cases of infection, LPS can modulate 
the suppression, and induce inflammatory chemokines that will recruit cytotoxic T cells to the maternal-fetal 
interface. Our results provide a possible mechanism by which infection can induce pregnancy complications such 
as preterm birth (Fig. 12).
As an anti-inflammatory agent, hCG may have therapeutic potential for prevention of miscarriage and pre-
term birth in pregnancies complicated by infection. Further clinical trials are needed to investigate the therapeu-
tic role of hCG for prevention of fetal loss.
Materials and Methods
All methods were performed in accordance with the relevant guidelines and regulations and 
approved by Yale University. Reagents and cell line. Reagents and cell line used in the experiments were 
as follows: LPS isolated from E. coli 0111:B4 (Sigma-Aldrich, St. Louis, MO), GSK-J4 and GSK126 were pur-
chased from (ApexBio, Houston, TX) and telomerase-immortalized human endometrial stromal cells (HESC) 
were developed in our laboratory and previously reported52,96.
Figure 12. Regulation of CXCL10 by hCG and its relevance during pregnancy. (A) hCG, through cAMP 
enhances the expression of EZH2 increasing H3K27me3 histone methylation which binds to region 4 of 
CXCL10 promoter region and consequently inhibiting CXCL10 expression. (B) Trophoblast derived hCG 
inhibits CXL10 expression by decidual cells preventing T cell recruitment.
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In-vitro decidualization of a uterine stromal cell line. HESC cell line was decidualized as previously 
described52,96. In short, HESC was cultured in DMEM low-glucose medium supplemented with 10% FBS (Gibco, 
Waltham, MA). Upon reaching confluency, the HESCs were switched to Optimem (Gibco, Waltham, MA) and 
treated for 7 days with 10 nM β2-estradiol, 1 μM medroxyprogesterone acetate, and 500 μM 8-bromo cyclic AMP. 
On day 8, the cells were trypsinized and the cell pellets were collected for RNA extraction.
Endometrial stromal cells conditioned media preparation. Human endometrial stromal cells 
(HESC) were plated at 5 × 105 cells/100 mm dish with 10% FBS DMEM-F12 media and allowed to attach over-
night. Upon reaching confluency, the uterine stromal cells were switched to Optimem (Gibco, Waltham, MA) and 
differentiated into decidual cells by treating them for 5 days with 10 nM β2-estradiol, 1 μM medroxyprogesterone 
acetate, and 500 μM 8-bromo cyclic AMPM. Control cells received vehicle for the same length of time. After 5 
days media was then changed to 1 Optimem media and incubated for additional 48 hrs. Cell supernatant was 
collected and spun down to remove any cellular debris. Cell free supernatant was aliquoted and stored at −80 °C 
until use.
Chromatin immunoprecipitation and ChIP-PCR. Chromatin immunoprecipitation (ChIP) was per-
formed on the treated uterine stromal cell line and the decidua tissue using the Zymo-Spin ChIP Kit according 
to the manufacturer’s instructions (Irvine, CA). Briefly, the tissue was mechanically homogenized, crosslinked, 
and then immunoprecipitation was performed using an anti-H3K27me3 antibody (Cell Signaling Technology, 
Danvers, MA) and a rabbit anti-IgG antibody (Santa Cruz Biotechnology, Dallas, TX). The ChIP DNA was puri-
fied and stored until they were ready for PCR.
The previously stored DNA purified after chromatin immunoprecipitation was used for PCR. Eight pairs of 
primers were designed to span the 1000 bp upstream of the human CXCL10gene in order to identify the binding 
site(s). The PCR product was then run on a 1% DNA Agarose gel and imaged using the Kodak Image Station 4000 
(Carestream Health, New Haven, CT). When the location of enrichment was identified (Region 4), that primer 
set was used for the subsequent ChIP PCR reactions. The purified ChIP DNA was used for real-time PCR using 
the primers from Region 4 to quantify the enrichment of the H3K27me3 histone to Region 4 of the CXCL10 
promoter.
Real-time PCR. RNA was isolated from the samples using the Qiagen RNeasy Mini Kit (Qiagen, Waltham, 
MA). cDNA was prepared using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) as previously 
described97.
Luminex multiplex assay. After culture and treatment, the supernatant was collected, centrifuged, ali-
quoted, and stored until use. The samples were thawed only once immediately prior to running the assay. The 
samples were run on the Luminex Multiplex Assay (R&D Systems, Minneapolis, MN) for the following cytokines 
and chemokines: GROa, IL-1b, IL-6, IL-8, IL-10, IL-12, IL-17, G-CSF, GM-CSF, IFN-Y, CXCL-10, MCP-1, 
MIP-1a, MIP-1b, RANTES, TNF-a, and VEGF.
Cell migration experiments. Transwell migration experiments were performed using conditioned media 
from the non-decidualized and decidualized uterine stromal cell line. PBMCs were seeded in 5µm-inserts (3 × 
105 cells/insert) (BD Falcon cell culture inserts), which then were set in a 24-well plate containing the conditioned 
media from the stromal cells under different treatments. After 24 hours, the cells were recovered from the lower 
compartment and the total number of migrating cells was quantified. In addition, the percentage of CD4 or CD8 
cells were quantified by FACS analysis. The results are expressed relative to basal conditioned for each assay.
Flow-cytometry analysis. T lymphocytes were stained with the following mAbs: mouse anti-human CD4 
PE conjugated, mouse and anti-human CD8 APC conjugated, according to the manufacturer’s instructions (BD 
Biosciences, San Jose, CA, USA). Briefly, after recovery, the cells were washed and surface stained with anti-CD4 
and anti-CD8. The levels of CD4 and CD8 T cells were then quantified.
Western blot. Western blot was performed using a monoclonal anti- H3K27me3 antibody (Cell Signaling 
Technology, Danvers, MA). The cells were lysed and sonicated with cell lysis buffer (Cell Signaling Technology, 
Danvers, MA) supplemented with protease inhibitors. Equal amounts of protein were boiled in SDS-containing 
sample buffer, resolved on SDS-PAGE, and immunoblotted with the anti-H3K27me3 antibody.
Organ culture experiments. The Institutional Review Board of Yale University approved the collection 
and use of these tissues for research purposes (HIC# 12696). Organ culture experiments were performed using 
decidual tissue isolated from the placentae of term uncomplicated non-labored pregnancies at the time of sched-
uled cesarean delivery. Immediately upon delivery, the decidua was separated from the fetal membranes, rinsed 
in phosphate buffered saline, and cut into approximately 3 × 3 mm pieces and placed in DMEM media supple-
mented with Normocin (InvivoGen, San Diego, CA) for 24 hours. The following day, the media was refreshed, 
the tissue was treated with either LPS or inhibitors, and after 24 hours, it was collected for RNA isolation or 
crosslinked for chromatin immunoprecipitation. Supp Fig. 1 shows a representative H&E stained slide of the 
decidua tissue used for the organ culture experiments.
Chromatin immunoprecipitation. Chromatin immunoprecipitation was performed on the treated uter-
ine stromal cell line and the decidua tissue using the Zymo-Spin ChIP Kit (Irvine, CA). Briefly, the tissue was 
mechanically homogenized using an Omni TH tissue homogenizer (Omni International, Kennesaw, GA) then all 
samples were crosslinked using 1% formaldehyde. The crosslinking reaction was stopped using 0.125 M glycine. 
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The samples were then washed with phosphate buffered saline supplemented with protease inhibitors, centri-
fuged, and stored at −80 °C until ready for use. Next, the samples were sonicated to a size of approximately 250 bp 
size using a Sonic Dismembrator 500 (Fisher Scientific, Waltham, MA). The size of the chromatin was confirmed 
by running the sheared chromatin on a DNA 1% Agarose gel. After sonication, the immunoprecipitation reac-
tion was performed using an anti-H3K27me3 antibody (Cell Signaling Technology, Danvers, MA) and a rabbit 
anti-IgG antibody (Santa Cruz Biotechnology, Dallas, TX) as a negative control and the ZymoMag Protein A 
beads supplied with the kit. The samples were washed with the provided wash buffers, then reverse crosslinked, 
and the resulting DNA was purified and stored until they were ready for PCR.
ChIP-qPCR. ChIP Primers used in this study: The 8 primer sequences corresponding to the location in the 
CXCL10 promoter are as follows:
Region 1: F: CCATTTTCCCTCCCTAATTC, R: CCTTCGAGTCTGCAACATG
Region 2: F: GTAGCCTCCAAGTTACGG, R: GAATGGATTGCAACCTTTG
Region 3: F: CAAAGGTTGCAATCCATTC, R: CACAACTTGCTGTTACC
Region 4: F: GAACAGTGATTTACCTGGACA, R: CTTGCCAGTTCCAGATCTTTG
Region 5: F: GACAGGGTCAAAGATCTGG, R: CCCTCAAAATAGTTATGTTGG
Region 6: F: CATTGCTCATTTGGGTATCTGA, R: CAATAACCCTAGGATAGCTATG
Region 7: F: AGGGTGCTTTTTGAGGA, R: ACAGTGTCTTGGAGCTGA
Region 8: F: CTCCAAGACACTGTTAAATG, R: GCCACGATTCATCATCC
Real-time PCR. Real-time PCR was performed using the following primers:
CXCL-10: F: CCCACGTGTTGAGATCATTG, R: TCCATCACAGCACCGGG,
JMJD3: F: AGTACCGCACTGAGGAGCTG, R: CAGTGCCCTCCTCCGCT,
EZH2: F: TGCACATCCTGACTTCTGTGA, R: TCATCTCCCATATAAGGAATGTTATG,
Prolactin: F: CATCAACAGCTGCCACACTT, R: CGTTTGGTTTGCTCCTCAAT,
IGFBP1: F: CTATGATGGCTCGAAGGCTC, R: TTCTTGTTGCAGTTTGGCAG,
GAPDH: F: TTAAAAGCAGCCCTGGTGAC, R: CTCTGCTCCTCCTGTTCGAC.
Patient recruitment and sample collection. The description of the patients population, recruitment and 
characteristics has been previously described98 as following:
IVF Cohort. Recruitment of IVF patients and storage of samples was approved by the Yale institutional Review 
Board (IRB) with no written consent requirement (#2000021607). All the participants had an informed consent 
for study participation. An aliquot of blood was assigned for the study during the regular blood test for monitor-
ing chemical pregnancy (hCG serum levels). The study was deemed to have minimal harm to patients so only 
verbal consent was requested. The investigators have no access to any personal information. Coded serum sam-
ples were provided to the investigators without any patient information.
Patients aged 18–44 undergoing fresh or frozen day 3 or day 5 (blastocyst) embryo transfer from October 2017 
to July 2018 were eligible for participation. Exclusion criteria were patients with chronic autoimmune disease 
(such as lupus, thyroid antibodies, ulcerative colitis, or Crohn’s disease), diabetes and hypertension requiring 
medication, endometriosis confirmed by laparoscopy, or current illness (in general, we excluded patients with an 
underlying inflammatory process). We also excluded patients with prior pregnancy losses, unless the tissue from 
the loss had undergone genetic testing and was determined to be chromosomally abnormal. Patients were asked 
to participate at the time of embryo transfer. Blood was collected by venipuncture into 10 mL vacutainer tubes 
starting at the time of the first positive β-hCG, 8–12 days after embryo transfer and then every 48 hours until 
an intrauterine pregnancy was confirmed using transvaginal ultrasound, or when a pregnancy was deemed as 
biochemical based on declining β-hCG levels following an initial positive test. Samples were left at room temper-
ature for 60 minutes to allow for clotting and then centrifuged (Thermo Scientific Sorvall ST 16, Waltham, MA) 
at 3,000 RPM for ten minutes at room temperature. Serum was aliquoted into 1.5 mL polypropylene RNase- and 
DNase-free microcentrifuge tubes and stored in −80 °C freezers until ready for testing.
Statistical analysis. Statistical analyses was done using the Statistical Package for Social Science (SPSS) for 
windows and GraphPad Prism software, version 5. Differences between two groups were analyzed using Student’s 
t-test. The differences between multiple groups were analyzed by one-way ANOVA and Chi-square test. P-values 
less than 0.05 were considered significant. All the experiments were done in triplicate and a minimum of three 
independent experiments.
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